ROIV ▼ -1.3% - Roivant Sciences Ltd. $ROIV ROIVW - Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus Roivant Sciences shares fell 1.3% following the company's announcement of topline results from its proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus. The decline suggests investors may have found the efficacy or safety data disappointing relative to prior expectations, though the headline does not specify the actual results. 23-SEP-2026 07:00 AM ET